Expand JAZZ Menu
JAZZ MENU

JAZZ Latest Press Releases

-- September 15, 2026 --

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences PRNewswire 9:01 AM

-- September 2, 2026 --

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences PRNewswire 4:15 PM

-- August 31, 2026 --

Ziihera (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA PRNewswire 6:00 AM

-- August 27, 2026 --

Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases PRNewswire 12:31 AM

-- August 26, 2026 --

Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases PRNewswire 7:00 AM

-- August 25, 2026 --

U.S. FDA Approves Ziihera (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma PRNewswire 10:02 AM

-- August 10, 2026 --

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio PRNewswire 7:30 AM

-- August 3, 2026 --

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results PRNewswire 4:05 PM

-- July 20, 2026 --

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 PRNewswire 4:15 PM

-- June 17, 2026 --

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies Business Wire 7:00 AM

-- June 16, 2026 --

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia PRNewswire 4:05 PM

-- June 12, 2026 --

Jazz Pharmaceuticals Provides Update on Zepzelca (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer PRNewswire 8:00 AM

-- June 4, 2026 --

Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia PRNewswire 7:45 AM

-- May 27, 2026 --

Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA PRNewswire 5:00 PM

-- May 12, 2026 --

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences PRNewswire 4:15 PM

-- May 5, 2026 --

Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results PRNewswire 4:05 PM
Market Data Delayed 15 Minutes